EGFR and glioblastoma: While previous investigations have failed to extend glioma patient survival using either EGFR-targeting agents or inhibitors of PI3K pathway components [37], we believe our findings are meaningful in designing clinical trials with osimertinib and MK-2206 for osimertinib-resistant GBM patients.